Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03921060 · ClinicalTrials.gov registry record · Phase 4
Markers of Osteoporosis in Cystic Fibrosis
A Phase 4 study of Cystic Fibrosis, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03921060 is a Phase 4 study of Cystic Fibrosis that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 100 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03921060, a Phase 4 study of Cystic Fibrosis, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return annually for repeat DEXA scans, micro CT, and blood collection.
Conditions Studied
Interventions
- DRUG Denosumab
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-09-02 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03921060
The ClinicalTrials.gov registry entry for NCT03921060 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (44% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Denosumab is the first listed.
NCT03921060 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03921060 about?
NCT03921060 is a clinical study titled "Markers of Osteoporosis in Cystic Fibrosis". Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study an...
What is the current status of trial NCT03921060?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2021-09-02. Estimated completion is 2027-07.
What conditions does trial NCT03921060 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT03921060?
The interventions under investigation include: Denosumab (DRUG).
Who is sponsoring clinical trial NCT03921060?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03921060 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BEGIN Novel ImagiNG Biomarkers
RECRUITING · Phase 4
-
Estrogen Supplementation and Bone Health in Women With CF
RECRUITING · Phase 4
-
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
RECRUITING · Phase 4
-
Hyperpolarized Imaging for New Treatments
ACTIVE NOT RECRUITING · Phase 4
-
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
ACTIVE NOT RECRUITING · Phase 4
-
PR-018: An Open-Label, Safety Extension of Study PR-011
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.